Desma

What Desma does

Desma is the regional brand identity under which Italy's SIT Group (Laboratorio Farmaceutico S.I.T. S.r.l., founded 1925) markets branded pharmaceutical products in Spain, France, and Germany, with further related entities in Italy (SIT Italy) and Switzerland (SIT Switzerland). The group manufactures and distributes therapeutic solutions made in Italy across six therapeutic areas — Central Nervous System, Cardiovascular, Respiratory, Gastrointestinal, Inflammation and Pain, and Nutritional deficiencies — with established consumer-facing brands such as Trofodermin (wound healing), Coryfin C (cough/cold), Rino Calyptol (nasal decongestant), Fomentil, and the Centellase derma-cosmetic line.

The portfolio combines organically developed heritage brands and brands acquired outright from major multinationals. Since 2020 SIT Group has acquired LOPRESSOR/ICAZ/MIOREL from Daiichi Sankyo France, SULMETIN and POTASION from Sanofi, NATIFAR/NATIMED from Laboratorios BIAL, and — across 2025 alone — DINTOINA (Italian CNS), MIZOLLEN and DERINOX (France, from Therabel entities), and OSTIDIL-D3/KEFORAL. The underlying technology stack is conventional pharmaceutical manufacturing and formulation, with no disclosed proprietary platforms, AI/ML capabilities, APIs, or data products.

Commercially, Desma/SIT operates a sales-led go-to-market through its own network of medical sales representatives engaging doctors and healthcare professionals, supplemented by pharmacy and wholesale distribution across more than 70 countries. Revenue accrues from one-time product sales of branded therapeutics; no subscription, SaaS, or licensing model applies. Customer segments are organised vertically by therapeutic area, with end users being patients and prescribing healthcare providers. Pricing is not publicly disclosed, and revenue figures are not reported. Ownership is private (Italian S.r.l.), with no observed external venture, private equity, or public-market capital.

Name

Desma

Legal name

Laboratorio Farmaceutico S.I.T. S.r.l.

Website

https://desmahealthcare.com

Company type

Private

Founded year

1925

Operating status

Operating

Headcount range

1–10 employees

Short description

Desma is the Spanish, French, and German regional brand of Italian pharma group SIT (founded 1925), manufacturing and distributing Made-in-Italy therapeutic products across CNS, cardiovascular, respiratory, gastrointestinal, inflammation/pain, and nutritional segments to patients and healthcare providers in 70+ countries.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industries

Specialty Care Pharmaceuticals (HLAIAAAB), Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK)

Keywords

• Pharmaceutical manufacturing
• Therapeutic solutions
• Branded pharmaceuticals
• Drug distribution
• Pharmaceutical portfolio

Headquarters

HQ city

Mede

HQ country

Italy

HQ region

Europe

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Marketing or Sales, Technology or R&D

Revenue model

1. Pharmaceutical Product Sales: Desma, as part of SIT Group, generates revenue through the manufacture and marketing of therapeutic pharmaceutical products. The company sells both proprietary brands and acquired established pharmaceutical products across multiple therapeutic areas including CNS, cardiovascular, respiratory, gastrointestinal, inflammation/pain, and nutritional deficiencies.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Desma, as part of SIT Group, manufactures and markets therapeutic pharmaceutical products Made in Italy across six therapeutic areas: Central Nervous System, Cardiovascular, Respiratory, Gastrointestinal, Inflammation/Pain, and Nutritional deficiencies. The portfolio includes both proprietary core brands (Centellase, Trofodermin, Coryfin C, Rino Calyptol, Fomentil) and acquired established brands from major pharmaceutical companies, distributed through wholly-owned European subsidiaries and pharmacy channels in 70+ countries.

Product overview

Desma is a regional pharmaceutical brand under SIT Group (an Italian pharmaceutical group with nearly 100 years of history), operating in Spain, France, and Germany. The company manufactures and markets therapeutic solutions Made in Italy across multiple therapeutic areas including Central Nervous System (CNS), Cardiovascular, Respiratory, Gastrointestinal, Inflammation and Pain, and Nutritional deficiencies. The product portfolio consists of both core branded products (Trofodermin, Coryfin C, Rino Calyptol, Fomentil, Centellase) and acquired brands from major pharmaceutical companies (Sanofi, Daiichi Sankyo, BIAL, Therabel). Recent acquisitions in 2025 include OSTIDIL-D3, KEFORAL, DERINOX, MIZOLLEN, and DINTOINA, expanding the company's European footprint.

Differentiator

Problem solved

Functional benefit

Brands

• Centellase: Dermatological/beauty product line including Centellase Vitalgambe, Gel Defaticante, and Contorno occhi for skin and beauty care.
• Trofodermin
• Coryfin
• Rino Calyptol
• Fomentil

Products and services

• Centellase Dermatological/skincare product line including Centellase Vitalgambe, Gel Defaticante, and Contorno occhi for skin and beauty care applications.
• Trofodermin Topical pharmaceutical product available in cream and spray formulations for wound healing and skin regeneration.
• Coryfin C Cough and cold remedy candy, available in sugar-free honey and ginger variant.
• Rino Calyptol Nasal spray product for relieving congested nose, featured in advertising campaigns with seasonal themes.
• Fomentil Pharmaceutical product featured in ambient marketing campaigns in Italian cities.
• DINTOINA Central Nervous System (CNS) pharmaceutical product acquired to expand the Italian portfolio.
• LOPRESSOR Cardiovascular pharmaceutical product acquired from Daiichi Sankyo France.
• DERINOX Brand acquired from Therabel Lucien Pharma Sas for the France market.
• MIZOLLEN Brand acquired from THERABEL HEALTHCARE LIMITED for the French pharmaceutical market.
• SULMETIN Established pharmaceutical product acquired from Sanofi.
• POTASION Pharmaceutical brand acquired from Sanofi.
• NATIFAR and NATIMED Brands acquired from Laboratorios BIAL (Spanish affiliate of BIAL Group).
• OSTIDIL-D3 and KEFORAL Pharmaceutical products acquired by SIT Pharma, part of the September 2025 portfolio expansion.

Segments6 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Eight partnerships are on record, tiered major and core.

• SIT Pharma (internal acquisition)majorStrategic or Co-development Partner · 16 September 2025SIT Pharma acquired OSTIDIL-D3 and KEFORAL products, expanding its pharmaceutical portfolio. This acquisition demonstrates the company's strategy of growing through product acquisitions from other pharmaceutical companies.
• Therabel Lucien Pharma SascoreStrategic or Co-development Partner · 2 September 2025SIT Pharma acquired DERINOX brand from Therabel Lucien Pharma Sas for the France market. This represents a strategic portfolio expansion for SIT Pharma's French operations through Desma France.
• Therabel Healthcare LimitedcoreStrategic or Co-development Partner · 1 July 2025SIT Pharma acquired MIZOLLEN brand from Therabel Healthcare Limited. This acquisition strengthens SIT Pharma's presence in the French pharmaceutical market.
• SIT Pharma (internal acquisition)majorStrategic or Co-development Partner · 2 April 2025SIT Pharma acquired DINTOINA to expand its Italian portfolio in the CNS (Central Nervous System) therapeutic area with essential and well-known products, maintaining therapeutic continuity for patients and healthcare providers.
• SanofimajorStrategic or Co-development Partner · 8 November 2022SIT Group acquired SULMETIN brand from Sanofi following an agreement signed on November 8, 2022. This acquisition expanded SIT's pharmaceutical product portfolio with an established brand.
• SanofimajorStrategic or Co-development Partner · 8 November 2022SIT Group acquired POTASION brand from Sanofi following an agreement signed on November 8, 2022. This represents a significant portfolio addition from a major pharmaceutical company.
• Laboratorios BIALmajorStrategic or Co-development Partner · 25 October 2022SIT Group acquired NATIFAR and NATIMED brands from Laboratorios BIAL, a Spanish affiliate of BIAL Group. This acquisition expanded SIT's portfolio with products from a leading Portuguese pharmaceutical group.
• Daiichi Sankyo FrancecoreStrategic or Co-development Partner · 30 June 2020SIT Group acquired LOPRESSOR, ICAZ, and MIOREL brands from Daiichi Sankyo France, effective June 30, 2020. This acquisition strengthened SIT's pharmaceutical presence in the French market through Desma France.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Recordati: Milan-based specialty and primary care pharmaceutical company with a similar European footprint and portfolio of acquired/established brands across multiple therapeutic areas. Comparable as an Italian mid-cap pharma with a buy-and-grow acquisition strategy.
• Molteni Farmaceutici: Italian specialty pharmaceutical company with focus on pain, CNS, and addiction therapy. Comparable as a privately held Italian pharma operating across multiple therapeutic categories with branded specialty products.
• Zambon: Privately held Italian pharmaceutical company with branded products across respiratory, pain, and CNS. Comparable as a mid-size family-owned Italian pharma with multi-area portfolio and European distribution focus.
• Italfarmaco: Privately held Italian pharmaceutical group with diverse therapeutic portfolio including cardiovascular, gynecological, and CNS products. Comparable as a privately held Italian mid-market pharma with multi-category branded portfolio.
• ABC Farmaceutici: Privately held Italian pharmaceutical company with branded specialty products in CNS, respiratory, and gastrointestinal therapeutic areas. Comparable as a mid-size Italian pharma with overlapping therapeutic focus and European distribution.

Broad incumbents

• Menarini Group: Large privately held Italian pharmaceutical group with diversified therapeutic portfolio and significant international distribution. Comparable as a broad incumbent in the Italian branded pharma space, though much larger and more diversified than Desma.
• Chiesi Farmaceutici: Privately held Italian pharmaceutical company with specialty focus in respiratory, cardiovascular, and rare diseases. Comparable as a larger Italian family-owned pharma operating in overlapping therapeutic areas.
• Angelini Pharma: Italian privately held pharmaceutical group active across CNS, pain, and infectious diseases. Comparable as another Italian branded pharma group with overlapping therapeutic areas and acquisitive growth history.

Emerging players

• Dompé: Italian biopharmaceutical company expanding into specialty and rare disease therapeutics. Comparable as an Italian pharma with branded specialty portfolio and international growth ambitions.

Others

• Therabel: European specialty pharma group that has been both a buyer and seller of mature brands, including the MIZOLLEN and DERINOX divestitures to Desma. Comparable as a counterparty in similar brand-divestiture transactions and as an adjacent European specialty pharma operator.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks4 records

Key highlights5 records

Customer concentration

• Facebookfacebook.com/Desmahealthcare
• LinkedInlinkedin.com/company/desma-healthcare

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Desma